Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy

Sponsor
Investigación en Hemofilia y Fisioterapia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05425888
Collaborator
Real Fundación Victoria Eugenia (Other)
32
1
2.8
11.5

Study Details

Study Description

Brief Summary

Introduction: Hemophilic ankle arthropathy is manifested by functional degenerative alterations (muscle strength deficit, mobility and proprioception), intra-articular and chronic pain.

Design: Case-control study. Objective: To observe the differences between patients with hemophilic ankle arthropathy and their healthy peers, regarding dorsiflexion, dorsiflexion strength, anterior tibial muscle activation, biomechanical analysis of gait and balance, and functionality.

Patients: 16 patients with hemophilic ankle arthropathy and 16 healthy subjects without ankle joint damage.

Measurement instruments and study variables: dorsiflexion (range of motion), dorsiflexion strength (dynamometry), anterior tibial muscle activation (surface electromyography), biomechanical analysis of gait and balance (RS SCAN® model platform), and functionality (2 Minute Walk Test).

Expected results: Analyze the main differences and their relationship based on the clinical and independent variables of patients with hemophilia, compared to their healthy peers.

Condition or Disease Intervention/Treatment Phase
  • Other: Hemophilia group

Study Design

Study Type:
Observational
Anticipated Enrollment :
32 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy. A Case-control Study
Anticipated Study Start Date :
Jun 22, 2022
Anticipated Primary Completion Date :
Jul 31, 2022
Anticipated Study Completion Date :
Sep 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Hemophilia group

Group of adult patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy

Other: Hemophilia group
Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.

Control group

Group of healthy subjects with sociodemographic characteristics similar to patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy.

Other: Hemophilia group
Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.

Outcome Measures

Primary Outcome Measures

  1. Assess the dorsal flexion with numerical scale of range of motion [Screening visit]

    Measurement with Leg Motion system. Subjects will stand with the big toe on the starting line and the knee touching a metal stick. The metal rod will move away from the foot up to the maximum ankle dorsiflexion allowed, without taking the heel off the ground and with knee contact on the rod. Three measurements will be made for each ankle and the mean value will be used for data analysis. All measurements will be made with the patient barefoot.

  2. Assess the dorsiflexion strength with dynamometry [Screening visit]

    The maximal isometric strength of the ankle flexor muscles will be tested. Both extremities will be evaluated with a manual dynamometer (model Lafayette Manual Muscle Tester 01165). The examiner will hold the dynamometer on the sole of the foot while the subject exerts maximal force against it. The unit of measurement of this measurement instrument is the Newton per square centimeter (N/cm2), where the higher the score, the greater the muscle force.

Secondary Outcome Measures

  1. Assess the electrical activity of the tibialis anterior muscle with electromyography [Screening visit]

    Using surface electromyography (model SHIMMMER2, Shimmer, Ireland), we will evaluate the electrical activity of the musculature and its level of activation. The placement of the electrodes will be marked on the standing subjects, and they will be placed following the European recommendations for the use of the SEMG. A bipolar SEMG system will be used with circular electrodes 10 mm in diameter, 20 mm apart, placed longitudinally, in the direction of the fibers of the studied muscle, and with a remote reference electrode

  2. Assess the biomechanical analysis of gait and balance with pressure platform [Screening visit]

    It will be evaluated using an Rs Scan® pressure platform and FootScan® pressure measurement system. This scientific version biomechanical examination device measures plantar pressure using an X-Y array of resistive pressure sensitive sensors that are scanned sequentially. The system records pressure data when the subject is standing or walking on the platform. Measurements will be made with the basic 0.5m platform with 4,096 sensors with resistive technology and 300Hz data acquisition frequency. The biomechanics of walking will be analyzed with the analysis of the probes and the static balance in a time of 30 seconds

  3. Assess the functionality with pressure platform [Screening visit]

    The 2-Minute Walking Test will be used. The functional capacity to exercise, in clinical practice, will be evaluated by means of a modified version, used in populations with pathologies with special characteristics, of the 6-minute version. It will be carried out in a closed corridor, with a length of 30 m delimited between cones. Before the test, participants must rest for at least 10 minutes. Subsequently, they will be instructed to complete the circuit by walking around the cones as fast as possible, but without running, for 2 minutes. They will be allowed to use walking aids, slow down or stop to rest if necessary. The distance covered at the end of the 2 minutes will be recorded by the evaluator. This instrument has shown excellent test-retest reliability.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients diagnosed with hemophilia A and B.

  • Over 18 years.

  • With medical diagnosis of ankle arthropathy.

  • With clinical evaluation by Hemophilia Joint Health Score.

  • In prophylactic treatment or on demand with FVIII / FIX concentrates for coagulation.

  • No previous hemarthrosis of the ankles in the 3 months prior to evaluation.

Exclusion Criteria:
  • Patients with inhibitors (antibodies against FVIII or FIX).

  • Patients with neurological or cognitive disorders that prevent the understanding of questionnaires and physical tests.

  • Failure to sign the informed consent document

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Oviedo Oviedo Asturias Spain 33006

Sponsors and Collaborators

  • Investigación en Hemofilia y Fisioterapia
  • Real Fundación Victoria Eugenia

Investigators

  • Principal Investigator: Rubén Cuesta-Barriuso, PhD, University of Oviedo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rubén Cuesta-Barriuso, Principal Investigator, University of Oviedo
ClinicalTrials.gov Identifier:
NCT05425888
Other Study ID Numbers:
  • He-AnkleCon
First Posted:
Jun 21, 2022
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rubén Cuesta-Barriuso, Principal Investigator, University of Oviedo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2022